Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of CTP-730 in Healthy Volunteers
NCT02239081Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Sep 2014
- Primary completion
- Jan 2015
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CTP-730 in psoriasis and psoriatic arthritis (PsA) (8 arms), sponsored by Concert Pharmaceuticals. Primary endpoints: Number and severity of adverse events at 3 days and Pharmacokinetics parameters at 96 hours. Started Sep 2014; status: completed.
02
Drugs
CTP-730
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02239081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02239081.